ClinicalTrials.gg
CompletedNCT02445586Updated Oct 29, 2019Results posted

Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer

A Phase 4 interventional study of Docetaxel and Pertuzumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 9 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Enrollment
141st of 248
52 · median 68
Started
2015
with 9 others
Phase 4
5 of 264
none open now
Registered
220th of 264
by date
Lead sponsor
16 of 264
Hoffmann-La Roche

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 141st largest by enrollment of the 248 interventional ones that give a count, is one of 10 that started in 2015, is one of 5 in phase 4, and was the 220th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase 4, single-arm, open-label, multicenter study to assess the safety and efficacy of pertuzumab in combination with trastuzumab and docetaxel for the treatment of participants with human epidermal growth factor receptor 2 (HER2)-positive advanced (locally recurrent, unresectable, or metastatic) breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For women of and men with partners of childbearing potential, agreement to use a highly-effective non-hormonal form of or two effective forms of non-hormonal contraception by the participant and/or partner
  • or cytologically confirmed and documented adenocarcinoma of the breast with or locally recurrent disease not amenable to curative resection; participants with measurable and/or non- are eligible
  • Known and documented -positive
  • Known and documented of at least 50 percent (%)
  • Adequate organ function
  • A negative serum beta-human chorionic gonadotropin (beta-HCG) test for women of childbearing potential (premenopausal, or less than [\<] 12 months of amenorrhea , and women who have not undergone surgical sterilization [absence of ovaries and/or uterus]) within 7 days prior to the first dose of study treatment with the result available prior to first dosing

Exclusion criteria

Exclusion Criteria:

  • Previous systemic non-hormonal anti-cancer therapy for the or locally recurrent disease
  • Pregnant or lactating women
  • Current clinical or radiographic evidence of central nervous system (CNS) metastases
  • Disease progression while receiving or within 12 months of completion of trastuzumab and/or lapatinib treatment in the or neo-adjuvant setting
  • History of decline to below 50% during or after prior trastuzumab adjuvant or neo-adjuvant therapy
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Pertuzumab in Combination with Trastuzumab and Docetaxel

    Participants will receive pertuzumab in combination with trastuzumab and docetaxel every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.

    Drug: Docetaxel · Drug: Pertuzumab · Drug: Trastuzumab

Interventions

  • Participants will receive docetaxel in line with locally approved Prescribing Information. After Cycle 6 (cycle length = 21 days), continuation of docetaxel treatment will be at the discretion of the investigator. Docetaxel will be administered after pertuzumab and trastuzumab.

  • Participants will receive pertuzumab at an initial dose of 840 milligrams (mg) as a 60-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 420 mg as a 30 to 60-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.

    Also known as: Perjeta®

  • Participants will receive trastuzumab at an initial dose of 8 milligrams per kilogram (mg/kg) as a 90-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 6 mg/kg as a 30 to 90-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.

    Also known as: Herceptin®, Herclon®

06

What researchers measure

Primary outcomes

  1. Overall Number of Participants by the Number of Serious Adverse Events Reported Per Participant

    The number of participants with serious adverse events was counted in the four following categories for number of events reported per participant: greater than or equal to (≥) 1, 1, greater than (\>) 1, or 0 serious adverse events. Participants with multiple occurrences of events (the ≥1 and \>1 serious adverse event categories) were only counted once per category.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  2. Overall Number of Participants With Serious Adverse Events by Severity (Initial and Most Extreme), According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03)

    The number of participants with serious adverse events was counted by the initial and most extreme levels of severity of the adverse event, assessed as Grades 1-5 according to NCI CTCAE v4.03. Any adverse event not specifically listed in NCI CTCAE v4.03 was assessed according to the following grades of severity: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening or urgent intervention indicated; and Grade 5 is death related to adverse event. The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an adverse event. The seriousness of an adverse event is based on whether it meets any of the criteria set out in the protocol's definition of a serious adverse event. Severity and seriousness were independently assessed for each adverse event. Participants with multiple occurrences of serious adverse events of the same severity were only counted once per severity category.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  3. Number of Participants With Serious Adverse Events Related to Docetaxel

    The number of participants with serious adverse events was counted for any serious adverse event that was related to study treatment with docetaxel, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  4. Number of Participants With Serious Adverse Events Related to Pertuzumab

    The number of participants with serious adverse events was counted for any serious adverse event that was related to study treatment with pertuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  5. Number of Participants With Serious Adverse Events Related to Trastuzumab

    The number of participants with serious adverse events was counted for any serious adverse event that was related to study treatment with trastuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  6. Overall Number of Participants With Serious Adverse Events by Action Taken With Study Drug

    The number of participants with serious adverse events was counted by the type of action taken with the study drug (docetaxel, pertuzumab, and trastuzumab) in response to the adverse event in the three following categories: infusion reduced, temporarily interrupted, or permanently discontinued. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of serious adverse events that required the same action to be taken with the study drug were only counted once per category.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  7. Overall Number of Participants With Serious Adverse Events by Event Outcome

    The number of participants with serious adverse events was counted by the event outcome in the six following categories: fatal, recovered/resolved, recovered/resolved with sequelae, recovering/resolving, not recovered/not resolved, or unknown. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of serious adverse events with the same outcome were only counted once per category.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  8. Number of Participants With Hematological Abnormalities Reported as Serious Adverse Events

    The number of participants with hematological laboratory abnormalities reported as serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  9. Number of Participants With Serum Chemistry Abnormalities Reported as Serious Adverse Events

    The number of participants with serum chemistry laboratory abnormalities reported as serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  10. Number of Participants With Coagulation Abnormalities Reported as Serious Adverse Events

    The number of participants with coagulation laboratory abnormalities reported as serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  11. Number of Participants Who Died Due to a Serious Adverse Event by Cause of Death

    The number of participants who died due to a serious adverse event was counted by the cause of death.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  12. Overall Number of Participants by the Number of Non-Serious Adverse Events Reported Per Participant

    The number of participants with non-serious adverse events was counted in the four following categories for number of events reported per participant: greater than or equal to (≥) 1, 1, greater than (\>) 1, or 0 non-serious adverse events. Participants with multiple occurrences of events (the ≥1 and \>1 non-serious adverse event categories) were only counted once per category.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  13. Overall Number of Participants With Non-Serious Adverse Events by Severity, According to NCI-CTCAE v4.03

    The number of participants with non-serious adverse events was counted by the severity level of the adverse event, assessed as Grades 1-5 according to NCI CTCAE v4.03. Any adverse event not specifically listed in NCI CTCAE v4.03 was assessed according to the following grades of severity: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening or urgent intervention indicated; and Grade 5 is death related to adverse event. The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an adverse event. The seriousness of an adverse event is based on whether it meets any of the criteria set out in the protocol's definition of a serious adverse event. Severity and seriousness were independently assessed for each adverse event. Participants with multiple occurrences of non-serious adverse events of the same severity were only counted once per severity category.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  14. Number of Participants With Non-Serious Adverse Events Related to Docetaxel

    The number of participants with non-serious adverse events was counted for any non-serious adverse event that was related to study treatment with docetaxel, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  15. Number of Participants With Non-Serious Adverse Events Related to Pertuzumab

    The number of participants with non-serious adverse events was counted for any non-serious adverse event that was related to study treatment with pertuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  16. Number of Participants With Non-Serious Adverse Events Related to Trastuzumab

    The number of participants with non-serious adverse events was counted for any non-serious adverse event that was related to study treatment with trastuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  17. Overall Number of Participants With Non-Serious Adverse Events by Chemotherapy Adjustment With Docetaxel and/or Trastuzumab

    The number of participants with non-serious adverse events was counted by the type of action taken with docetaxel and/or trastuzumab in response to the adverse event in the three following categories: no adjustment, dosage modified/interrupted, and discontinued. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of non-serious adverse events that required the same action to be taken with the study drug were only counted once per category.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  18. Overall Number of Participants With Non-Serious Adverse Events by Action Taken With Pertuzumab

    The number of participants with non-serious adverse events was counted by the type of action taken with pertuzumab in response to the adverse event in the three following categories: no action taken, infusion slow down, infusion interrupted, and appropriate medical therapies administered. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of non-serious adverse events that required the same action to be taken with the study drug were only counted once per category.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  19. Overall Number of Participants With Non-Serious Adverse Events by Event Outcome

    The number of participants with non-serious adverse events was counted by the event outcome in the four following categories: resolved with no sequelae, resolved with sequelae, unresolved, or death. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of non-serious adverse events with the same outcome were only counted once per category.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  20. Overall Number of Participants With Non-Serious Adverse Events by Treatment Emergence (TEAE Versus Non-TEAE)

    The number of participants with non-serious adverse events was counted according to whether the event was considered a treatment emergent adverse event (TEAE), which is defined as an adverse event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state. Participants with multiple occurrences of non-serious adverse events were only counted once per category.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  21. Number of Participants With Hematological Abnormalities Reported as Non-Serious Adverse Events

    The number of participants with hematological laboratory abnormalities reported as non-serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  22. Number of Participants With Serum Chemistry Abnormalities Reported as Non-Serious Adverse Events

    The number of participants with serum chemistry laboratory abnormalities reported as non-serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  23. Number of Participants With Coagulation Abnormalities Reported as Non-Serious Adverse Events

    The number of participants with coagulation laboratory abnormalities reported as non-serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.

    Time frame: From Baseline until end of study (up to approximately 3 years)

  24. Number of Participants With Congestive Heart Failure

    Time frame: From Baseline until end of study (up to approximately 3 years)

  25. Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time

    Left ventricular ejection fraction (LVEF) assessments were performed within 42 days of enrollment and every three treatment cycles by either echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan; ECHO was the preferred method. In order to be eligible for this study, an LVEF of ≥50% was required at screening. The same method of LVEF assessment for each participant must have been used throughout the study, and to the extent possible, have been obtained at the same institution.

    Time frame: Baseline, every 3 cycles (1 cycle is 21 days) until treatment discontinuation, at Safety Follow-Up (28 days after last dose of study drug) and every 3 months thereafter until end of study (up to approximately 3 years)

  26. Number of Participants by Left Ventricular Ejection Fraction (LVEF) Findings Over Time

    Left ventricular ejection fraction (LVEF) assessments were performed within 42 days of enrollment and every three treatment cycles by either echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan; ECHO was the preferred method. In order to be eligible for this study, an LVEF greater than or equal to (≥)50% was required at screening. The same method of LVEF assessment for each participant must have been used throughout the study, and to the extent possible, have been obtained at the same institution. The following are definitions for the three categories of LVEF findings: 'Normal' was defined as LVEF ≥45%; 'Abnormal but not clinically significant' was defined as LVEF \<45% but not clinically significant in the investigator's judgment; 'Abnormal and clinically significant' was defined as LVEF \<45% and clinically significant in the investigator's judgment.

    Time frame: Baseline, every 3 cycles (1 cycle is 21 days) until treatment discontinuation, at Safety Follow-Up (28 days after last dose of study drug) and every 3 months thereafter until end of study (up to approximately 3 years)

  27. Number of Participants With Adverse Events Leading to Treatment Discontinuation

    The number of participants with any adverse event (serious or non-serious) that led to treatment discontinuation during the study was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one adverse event that led to treatment discontinuation may have been reported per participant.

    Time frame: From Baseline until end of study (up to approximately 3 years)

Secondary outcomes

  1. Overall Response Rate

    The overall response rate (ORR) was defined as the percentage of participants with best overall response of Complete Response (CR) or Partial Response (PR), confirmed by repeat assessment no less than 4 weeks after the response criteria were first met, using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Participants who either had not achieved CR or PR or were without a post-baseline tumor assessment were to be considered non-responders. All measurable and non-measurable lesions were documented at screening and re-assessed at each subsequent tumor evaluation. Response was assessed by the investigator on the basis of physical examinations, computed tomography (CT) scans, and magnetic resonance imaging (MRI). The same radiographic procedure was used throughout the study, and assessments were preferably performed by the same evaluator. The 95% confidence intervals were calculated using Clopper-Pearson methodology.

    Time frame: From Baseline up to disease progression or death (assessed at every 9 weeks, up to approximately 3 years)

  2. Number of Participants by Best Overall Response

    The best overall response was defined as the best response, out of all the documented responses over the course of the entire study period, using RECIST v1.1. All measurable and non-measurable lesions were documented at screening and re-assessed at each subsequent tumor evaluation. Response was assessed by the investigator on the basis of physical examinations, computed tomography (CT) scans, and magnetic resonance imaging (MRI). The same radiographic procedure was used throughout the study, and assessments were preferably performed by the same evaluator.

    Time frame: From Baseline up to disease progression or death (assessed at every 9 weeks, up to approximately 3 years)

  3. Number of Participants With Disease Progression or Death or Who Were Censored for Progression-Free Survival Analysis

    Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Participants who had not progressed or died or were lost to follow up at the time of the analysis were censored on the last visit at which assessment for progression was done (2 years after the last participant was enrolled). PFS was analyzed by the Kaplan-Meier method.

    Time frame: From Baseline up to disease progression or death (assessed at every 9 weeks, up to approximately 3 years)

  4. Median Duration of Progression-Free Survival

    Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Participants who had not progressed or died, or were lost to follow up at the time of the analysis, were censored on the last visit at which assessment for progression was done (2 years after the last participant was enrolled). PFS was analyzed by the Kaplan-Meier method.

    Time frame: From Baseline up to disease progression or death (assessed at every 9 weeks, up to approximately 3 years)

  5. Probability of Participants Remaining Event-Free in Progression-Free Survival From 2 to 32 Months

    Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Participants who had not progressed, died or were lost to follow up at the time of the analysis were censored on the last visit at which assessment for progression was done (2 years after the last participant was enrolled). PFS was analyzed by the Kaplan-Meier method.

    Time frame: Months 2, 3, 5, 6, 7, 8, 9, 11, 13, 15, 16, 17, 18, 19, 23, 24, 25, 27, 29, and 32

  6. Number of Participants Who Died or Were Censored for Overall Survival Analysis

    Overall survival was defined as the time from enrollment to the the date of death from any cause. Participants who were alive at the time of the analysis, dropped out of the study, or lost to follow-up were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication, and participants with no post-baseline information were censored at baseline. Overall survival was analyzed by the Kaplan-Meier method.

    Time frame: From Baseline up to death from any cause (up to approximately 3 years)

  7. Median Duration of Overall Survival

    Overall survival was defined as the time from enrollment to the the date of death from any cause. Participants who were alive at the time of the analysis, dropped out of the study, or lost to follow-up were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication, and participants with no post-baseline information were censored at baseline. Overall survival was analyzed by the Kaplan-Meier method.

    Time frame: From Baseline up to death from any cause (up to approximately 3 years)

  8. Probability of Participants Remaining Alive in Overall Survival From 3 to 34 Months

    Overall survival was defined as the time from enrollment to the the date of death from any cause. Participants who were alive at the time of the analysis, dropped out of the study, or lost to follow-up were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication, and participants with no post-baseline information were censored at baseline. Overall survival was analyzed by the Kaplan-Meier method.

    Time frame: Months 3, 9, 13, 14, 15, 18, 19, 20, 24, 25, 27, 32, 33, and 34

07

Results

Posted Oct 29, 2019

Participant flow

Participant flow — Overall Study
MilestonePertuzumab in Combination With Trastuzumab and Docetaxel
Started52
Received at least one dose of study drug52
Completed13
Not completed39
Withdrew: Death14
Withdrew: Withdrawal by subject13
Withdrew: Disease progression10
Withdrew: Protocol violation1
Withdrew: Medical condition1

Outcome measures

PrimaryOverall Number of Participants by the Number of Serious Adverse Events Reported Per Participant

The number of participants with serious adverse events was counted in the four following categories for number of events reported per participant: greater than or equal to (≥) 1, 1, greater than (\>) 1, or 0 serious adverse events. Participants with multiple occurrences of events (the ≥1 and \>1 serious adverse event categories) were only counted once per category.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Overall Number of Participants by the Number of Serious Adverse Events Reported Per Participant
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
≥1 Serious Adverse Event31
1 Serious Adverse Event17
>1 Serious Adverse Events14
0 Serious Adverse Events21
PrimaryOverall Number of Participants With Serious Adverse Events by Severity (Initial and Most Extreme), According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03)

The number of participants with serious adverse events was counted by the initial and most extreme levels of severity of the adverse event, assessed as Grades 1-5 according to NCI CTCAE v4.03. Any adverse event not specifically listed in NCI CTCAE v4.03 was assessed according to the following grades of severity: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening or urgent intervention indicated; and Grade 5 is death related to adverse event. The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an adverse event. The seriousness of an adverse event is based on whether it meets any of the criteria set out in the protocol's definition of a serious adverse event. Severity and seriousness were independently assessed for each adverse event. Participants with multiple occurrences of serious adverse events of the same severity were only counted once per severity category.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Overall Number of Participants With Serious Adverse Events by Severity (Initial and Most Extreme), According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03)
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Initial Severity - Grade 11
Initial Severity - Grade 24
Initial Severity - Grade 315
Initial Severity - Grade 47
Initial Severity - Grade 514
Most Extreme Severity - Grade 11
Most Extreme Severity - Grade 23
Most Extreme Severity - Grade 316
Most Extreme Severity - Grade 47
Most Extreme Severity - Grade 515
PrimaryNumber of Participants With Serious Adverse Events Related to Docetaxel

The number of participants with serious adverse events was counted for any serious adverse event that was related to study treatment with docetaxel, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events Related to Docetaxel
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Any Serious AEs Related to Docetaxel15
Diarrhoea5
Left ventricular dysfunction2
Fatigue2
Sinus tachycardia1
Abdominal pain1
Febrile neutropenia1
Enteritis1
Salivary hypersecretion1
Stomatitis1
Vomiting1
Pyrexia1
Device related sepsis1
Septic shock1
Infusion related reaction1
Rash1
PrimaryNumber of Participants With Serious Adverse Events Related to Pertuzumab

The number of participants with serious adverse events was counted for any serious adverse event that was related to study treatment with pertuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events Related to Pertuzumab
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Any Serious AEs Related to Pertuzumab13
Diarrhoea4
Ejection fraction decreased3
Left ventricular dysfunction2
Sinus tachycardia1
Abdominal pain1
Enteritis1
Stomatitis1
Fatigue1
Pyrexia1
Gastroenteritis1
Dyspnoea1
Rash1
Shock1
PrimaryNumber of Participants With Serious Adverse Events Related to Trastuzumab

The number of participants with serious adverse events was counted for any serious adverse event that was related to study treatment with trastuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events Related to Trastuzumab
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Any Serious AEs Related to Trastuzumab10
Ejection fraction decreased3
Left ventricular dysfunction2
Diarrhoea2
Enteritis1
Fatigue1
Pyrexia1
Sinus tachycardia1
Rash1
Shock1
PrimaryOverall Number of Participants With Serious Adverse Events by Action Taken With Study Drug

The number of participants with serious adverse events was counted by the type of action taken with the study drug (docetaxel, pertuzumab, and trastuzumab) in response to the adverse event in the three following categories: infusion reduced, temporarily interrupted, or permanently discontinued. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of serious adverse events that required the same action to be taken with the study drug were only counted once per category.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Overall Number of Participants With Serious Adverse Events by Action Taken With Study Drug
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Infusion of Docetaxel Reduced0
Infusion of Docetaxel Temporarily Interrupted1
Infusion of Docetaxel Permanently Discontinued1
Infusion of Pertuzumab Reduced0
Infusion of Pertuzumab Temporarily Interrupted3
Infusion of Pertuzumab Permanently Discontinued4
Infusion of Trastuzumab Reduced0
Infusion of Trastuzumab Temporarily Interrupted3
Infusion of Trastuzumab Permanently Discontinued5
PrimaryOverall Number of Participants With Serious Adverse Events by Event Outcome

The number of participants with serious adverse events was counted by the event outcome in the six following categories: fatal, recovered/resolved, recovered/resolved with sequelae, recovering/resolving, not recovered/not resolved, or unknown. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of serious adverse events with the same outcome were only counted once per category.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Overall Number of Participants With Serious Adverse Events by Event Outcome
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Fatal15
Recovered / Resolved18
Recovered / Resolved with Sequelae1
Recovering / Resolving3
Not Recovered / Not Resolved2
Unknown0
PrimaryNumber of Participants With Hematological Abnormalities Reported as Serious Adverse Events

The number of participants with hematological laboratory abnormalities reported as serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Hematological Abnormalities Reported as Serious Adverse Events
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Number of Participants With Hematological Abnormalities Reported as Serious Adverse Events2
PrimaryNumber of Participants With Serum Chemistry Abnormalities Reported as Serious Adverse Events

The number of participants with serum chemistry laboratory abnormalities reported as serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Serum Chemistry Abnormalities Reported as Serious Adverse Events
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Number of Participants With Serum Chemistry Abnormalities Reported as Serious Adverse Events0
PrimaryNumber of Participants With Coagulation Abnormalities Reported as Serious Adverse Events

The number of participants with coagulation laboratory abnormalities reported as serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one serious adverse event may have been reported per participant. Participants with multiple occurrences of the same serious adverse event were only counted once per preferred term.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Coagulation Abnormalities Reported as Serious Adverse Events
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Number of Participants With Coagulation Abnormalities Reported as Serious Adverse Events1
PrimaryNumber of Participants Who Died Due to a Serious Adverse Event by Cause of Death

The number of participants who died due to a serious adverse event was counted by the cause of death.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants Who Died Due to a Serious Adverse Event by Cause of Death
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Disease progression10
Sepsis and disease progression1
Dyspnoea1
Septic shock1
Shock1
Unknown cause1
PrimaryOverall Number of Participants by the Number of Non-Serious Adverse Events Reported Per Participant

The number of participants with non-serious adverse events was counted in the four following categories for number of events reported per participant: greater than or equal to (≥) 1, 1, greater than (\>) 1, or 0 non-serious adverse events. Participants with multiple occurrences of events (the ≥1 and \>1 non-serious adverse event categories) were only counted once per category.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Overall Number of Participants by the Number of Non-Serious Adverse Events Reported Per Participant
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
≥1 Non-Serious Adverse Event47
1 Non-Serious Adverse Event11
>1 Non-Serious Adverse Events36
0 Non-Serious Adverse Events5
PrimaryOverall Number of Participants With Non-Serious Adverse Events by Severity, According to NCI-CTCAE v4.03

The number of participants with non-serious adverse events was counted by the severity level of the adverse event, assessed as Grades 1-5 according to NCI CTCAE v4.03. Any adverse event not specifically listed in NCI CTCAE v4.03 was assessed according to the following grades of severity: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening or urgent intervention indicated; and Grade 5 is death related to adverse event. The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an adverse event. The seriousness of an adverse event is based on whether it meets any of the criteria set out in the protocol's definition of a serious adverse event. Severity and seriousness were independently assessed for each adverse event. Participants with multiple occurrences of non-serious adverse events of the same severity were only counted once per severity category.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Overall Number of Participants With Non-Serious Adverse Events by Severity, According to NCI-CTCAE v4.03
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Grade 138
Grade 234
Grade 312
Grade 41
Grade 50
PrimaryNumber of Participants With Non-Serious Adverse Events Related to Docetaxel

The number of participants with non-serious adverse events was counted for any non-serious adverse event that was related to study treatment with docetaxel, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Non-Serious Adverse Events Related to Docetaxel
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Any Non-Serious AEs Related to Docetaxel30
Diarrhoea12
Anaemia7
Stomatitis6
Leukopenia4
Alopecia4
Vomiting4
Pain4
Fatigue4
Oedema peripheral3
Skin ulcer2
Hypokalaemia2
Lacrimation increased2
Asthenia2
Pyrexia2
Paraesthesia2
Peripheral sensory neuropathy2
Dry skin2
Rash2
Skin exfoliation2
Muscular weakness1
Febrile neutropenia1
Thrombocytopenia1
Sinus tachycardia1
Abdominal pain1
Anal fistula1
Anorectal discomfort1
Constipation1
Frequent bowel movements1
Gastritis1
Haemorrhoidal haemorrhage1
Hyperchlorhydria1
Oral discomfort1
Chest pain1
Peripheral swelling1
Genital herpes1
Pyoderma1
Skin infection1
Urinary tract infection1
Liver function test abnormal1
Decreased appetite1
Hypomagnesaemia1
Hypophosphataemia1
Joint swelling1
Limb discomfort1
Pain in extremity1
Burning sensation1
Neuropathy peripheral1
Productive cough1
Dermatitis acneiform1
Rash maculo-papular1
Seborrhoeic dermatitis1
Skin hypertrophy1
Stevens-Johnson syndrome1
PrimaryNumber of Participants With Non-Serious Adverse Events Related to Pertuzumab

The number of participants with non-serious adverse events was counted for any non-serious adverse event that was related to study treatment with pertuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Non-Serious Adverse Events Related to Pertuzumab
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Any Non-Serious AEs Related to Pertuzumab20
Diarrhoea10
Stomatitis5
Pain3
Ejection fraction decreased3
Rash3
Lacrimation increased2
Chills2
Nasal dryness2
Dry skin2
Oedema peripheral1
Skin ulcer1
Left ventricular dysfunction1
Sinus tachycardia1
Abdominal discomfort1
Generalised oedema1
Pyrexia1
Hypokalaemia1
Hypomagnesaemia1
Myalgia1
Burning sensation1
Neuropathy peripheral1
Breast discomfort1
Productive cough1
Dermatitis acneiform1
Onycholysis1
Rash maculo-papular1
PrimaryNumber of Participants With Non-Serious Adverse Events Related to Trastuzumab

The number of participants with non-serious adverse events was counted for any non-serious adverse event that was related to study treatment with trastuzumab, in the investigator's judgment. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Non-Serious Adverse Events Related to Trastuzumab
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Number of Participants With Non-Serious Adverse Events Related to Trastuzumab0
PrimaryOverall Number of Participants With Non-Serious Adverse Events by Chemotherapy Adjustment With Docetaxel and/or Trastuzumab

The number of participants with non-serious adverse events was counted by the type of action taken with docetaxel and/or trastuzumab in response to the adverse event in the three following categories: no adjustment, dosage modified/interrupted, and discontinued. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of non-serious adverse events that required the same action to be taken with the study drug were only counted once per category.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Overall Number of Participants With Non-Serious Adverse Events by Chemotherapy Adjustment With Docetaxel and/or Trastuzumab
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
No Adjustment45
Dosage Modified / Interrupted9
Discontinued7
PrimaryOverall Number of Participants With Non-Serious Adverse Events by Action Taken With Pertuzumab

The number of participants with non-serious adverse events was counted by the type of action taken with pertuzumab in response to the adverse event in the three following categories: no action taken, infusion slow down, infusion interrupted, and appropriate medical therapies administered. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of non-serious adverse events that required the same action to be taken with the study drug were only counted once per category.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Overall Number of Participants With Non-Serious Adverse Events by Action Taken With Pertuzumab
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
No Action Taken47
Infusion Slow Down0
Infusion Interrupted0
Appropriate Medical Therapies Administered0
PrimaryOverall Number of Participants With Non-Serious Adverse Events by Event Outcome

The number of participants with non-serious adverse events was counted by the event outcome in the four following categories: resolved with no sequelae, resolved with sequelae, unresolved, or death. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of non-serious adverse events with the same outcome were only counted once per category.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Overall Number of Participants With Non-Serious Adverse Events by Event Outcome
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Resolved with No Sequelae42
Resolved with Sequelae12
Unresolved27
Death2
PrimaryOverall Number of Participants With Non-Serious Adverse Events by Treatment Emergence (TEAE Versus Non-TEAE)

The number of participants with non-serious adverse events was counted according to whether the event was considered a treatment emergent adverse event (TEAE), which is defined as an adverse event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state. Participants with multiple occurrences of non-serious adverse events were only counted once per category.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Overall Number of Participants With Non-Serious Adverse Events by Treatment Emergence (TEAE Versus Non-TEAE)
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
TEAEs47
Non-TEAEs3
PrimaryNumber of Participants With Hematological Abnormalities Reported as Non-Serious Adverse Events

The number of participants with hematological laboratory abnormalities reported as non-serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Hematological Abnormalities Reported as Non-Serious Adverse Events
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Anaemia8
Leukopenia4
Neutropenia2
Febrile neutropenia1
Iron deficiency1
Thrombocytopenia1
PrimaryNumber of Participants With Serum Chemistry Abnormalities Reported as Non-Serious Adverse Events

The number of participants with serum chemistry laboratory abnormalities reported as non-serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Serum Chemistry Abnormalities Reported as Non-Serious Adverse Events
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Hypomagnesaemia4
Hypokalaemia2
Hypoalbuminaemia1
Hypophosphataemia1
Hyperglycaemia1
Hyperuricaemia1
Liver function test abnormal1
PrimaryNumber of Participants With Coagulation Abnormalities Reported as Non-Serious Adverse Events

The number of participants with coagulation laboratory abnormalities reported as non-serious adverse events was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one non-serious adverse event may have been reported per participant. Participants with multiple occurrences of the same non-serious adverse event were only counted once per preferred term.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Coagulation Abnormalities Reported as Non-Serious Adverse Events
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Thrombocytopenia1
Anal haemorrhage1
Haemorrhoidal haemorrhage1
Rectal haemorrhage1
Upper gastrointestinal haemorrhage1
Vaginal haemorrhage1
Thrombophlebitis1
PrimaryNumber of Participants With Congestive Heart Failure
Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Congestive Heart Failure
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Number of Participants With Congestive Heart Failure0
PrimaryChange From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time

Left ventricular ejection fraction (LVEF) assessments were performed within 42 days of enrollment and every three treatment cycles by either echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan; ECHO was the preferred method. In order to be eligible for this study, an LVEF of ≥50% was required at screening. The same method of LVEF assessment for each participant must have been used throughout the study, and to the extent possible, have been obtained at the same institution.

Time frame:
Baseline, every 3 cycles (1 cycle is 21 days) until treatment discontinuation, at Safety Follow-Up (28 days after last dose of study drug) and every 3 months thereafter until end of study (up to approximately 3 years)
Reported as:
Mean · percentage points of LVEF
Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time
percentage points of LVEFPertuzumab in Combination With Trastuzumab and Docetaxel
Baseline (BL) - Value at Visit59.6 ± 3.92
Change from BL at Cycle 3-0.7 ± 2.95
Change from BL at Cycle 6-0.8 ± 4.09
Change from BL at Cycle 9-0.2 ± 4.43
Change from BL at Cycle 120.2 ± 3.99
Change from BL at Cycle 15-0.8 ± 4.33
Change from BL at Cycle 18-1.3 ± 4.07
Change from BL at Cycle 21-1.8 ± 5.72
Change from BL at Cycle 24-0.7 ± 4.03
Change from BL at Cycle 270.0 ± 2.83
Change from BL at Cycle 30-1.3 ± 6.55
Change from BL at Cycle 33-0.5 ± 3.21
Change from BL at Cycle 360.0 ± 2.90
Change from BL at Cycle 39-1.3 ± 3.51
Change from BL at Cycle 421.0 ± 0
Change from BL at Cycle 450.0 ± 1.41
Change from BL at Cycle 48-2.0 ± 2.83
Change from BL at Cycle 51-18.0 ± NA
Change from BL at Safety Follow-Up-4.3 ± 12.98
Change from BL at 3 Month Follow-Up-2.1 ± 4.80
Change from BL at 6 Month Follow-Up-1.8 ± 4.41
Change from BL at 9 Month Follow-Up-3.4 ± 6.44
Change from BL at 12 Month Follow-Up-2.3 ± 4.40
Change from BL at 15 Month Follow-Up-4.7 ± 5.51
Change from BL at 18 Month Follow-Up-10.0 ± 7.07
Change from BL at 21 Month Follow-Up-5.0 ± NA
Change from BL at 24 Month Follow-Up-5.0 ± NA
PrimaryNumber of Participants by Left Ventricular Ejection Fraction (LVEF) Findings Over Time

Left ventricular ejection fraction (LVEF) assessments were performed within 42 days of enrollment and every three treatment cycles by either echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan; ECHO was the preferred method. In order to be eligible for this study, an LVEF greater than or equal to (≥)50% was required at screening. The same method of LVEF assessment for each participant must have been used throughout the study, and to the extent possible, have been obtained at the same institution. The following are definitions for the three categories of LVEF findings: 'Normal' was defined as LVEF ≥45%; 'Abnormal but not clinically significant' was defined as LVEF \<45% but not clinically significant in the investigator's judgment; 'Abnormal and clinically significant' was defined as LVEF \<45% and clinically significant in the investigator's judgment.

Time frame:
Baseline, every 3 cycles (1 cycle is 21 days) until treatment discontinuation, at Safety Follow-Up (28 days after last dose of study drug) and every 3 months thereafter until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants by Left Ventricular Ejection Fraction (LVEF) Findings Over Time
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Baseline — Normal50
Baseline — Abnormal But Not Clinically Significant2
Baseline — Abnormal and Clinically Significant0
Cycle 3 — Normal48
Cycle 3 — Abnormal But Not Clinically Significant3
Cycle 3 — Abnormal and Clinically Significant0
Cycle 6 — Normal37
Cycle 6 — Abnormal But Not Clinically Significant3
Cycle 6 — Abnormal and Clinically Significant0
Cycle 9 — Normal24
Cycle 9 — Abnormal But Not Clinically Significant1
Cycle 9 — Abnormal and Clinically Significant1
Cycle 12 — Normal17
Cycle 12 — Abnormal But Not Clinically Significant0
Cycle 12 — Abnormal and Clinically Significant0
Cycle 15 — Normal16
Cycle 15 — Abnormal But Not Clinically Significant2
Cycle 15 — Abnormal and Clinically Significant0
Cycle 18 — Normal11
Cycle 18 — Abnormal But Not Clinically Significant2
Cycle 18 — Abnormal and Clinically Significant0
Cycle 21 — Normal10
Cycle 21 — Abnormal But Not Clinically Significant1
Cycle 21 — Abnormal and Clinically Significant1
Cycle 24 — Normal8
Cycle 24 — Abnormal But Not Clinically Significant1
Cycle 24 — Abnormal and Clinically Significant0
Cycle 27 — Normal5
Cycle 27 — Abnormal But Not Clinically Significant2
Cycle 27 — Abnormal and Clinically Significant0
Cycle 30 — Normal3
Cycle 30 — Abnormal But Not Clinically Significant1
Cycle 30 — Abnormal and Clinically Significant0
Cycle 33 — Normal5
Cycle 33 — Abnormal But Not Clinically Significant1
Cycle 33 — Abnormal and Clinically Significant0
Cycle 36 — Normal5
Cycle 36 — Abnormal But Not Clinically Significant1
Cycle 36 — Abnormal and Clinically Significant0
Cycle 39 — Normal2
Cycle 39 — Abnormal But Not Clinically Significant1
Cycle 39 — Abnormal and Clinically Significant0
Cycle 42 — Normal2
Cycle 42 — Abnormal But Not Clinically Significant0
Cycle 42 — Abnormal and Clinically Significant0
Cycle 45 — Normal2
Cycle 45 — Abnormal But Not Clinically Significant0
Cycle 45 — Abnormal and Clinically Significant0
Cycle 48 — Normal2
Cycle 48 — Abnormal But Not Clinically Significant0
Cycle 48 — Abnormal and Clinically Significant0
Cycle 51 — Normal0
Cycle 51 — Abnormal But Not Clinically Significant0
Cycle 51 — Abnormal and Clinically Significant1
Safety Follow-Up — Normal24
Safety Follow-Up — Abnormal But Not Clinically Significant1
Safety Follow-Up — Abnormal and Clinically Significant3
3 Month Follow-Up — Normal17
3 Month Follow-Up — Abnormal But Not Clinically Significant3
3 Month Follow-Up — Abnormal and Clinically Significant0
6 Month Follow-Up — Normal18
6 Month Follow-Up — Abnormal But Not Clinically Significant0
6 Month Follow-Up — Abnormal and Clinically Significant0
9 Month Follow-Up — Normal13
9 Month Follow-Up — Abnormal But Not Clinically Significant0
9 Month Follow-Up — Abnormal and Clinically Significant1
12 Month Follow-Up — Normal10
12 Month Follow-Up — Abnormal But Not Clinically Significant0
12 Month Follow-Up — Abnormal and Clinically Significant0
15 Month Follow-Up — Normal3
15 Month Follow-Up — Abnormal But Not Clinically Significant0
15 Month Follow-Up — Abnormal and Clinically Significant0
18 Month Follow-Up — Normal2
18 Month Follow-Up — Abnormal But Not Clinically Significant0
18 Month Follow-Up — Abnormal and Clinically Significant0
21 Month Follow-Up — Normal1
21 Month Follow-Up — Abnormal But Not Clinically Significant0
21 Month Follow-Up — Abnormal and Clinically Significant0
24 Month Follow-Up — Normal1
24 Month Follow-Up — Abnormal But Not Clinically Significant0
24 Month Follow-Up — Abnormal and Clinically Significant0
PrimaryNumber of Participants With Adverse Events Leading to Treatment Discontinuation

The number of participants with any adverse event (serious or non-serious) that led to treatment discontinuation during the study was counted. Adverse events (AEs) were encoded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. More than one adverse event that led to treatment discontinuation may have been reported per participant.

Time frame:
From Baseline until end of study (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Treatment Discontinuation
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Any AEs Leading to Treatment Discontinuation16
Disease progression5
Ejection fraction decreased3
Headache2
Anaemia1
Death1
Diarrhoea1
Dyspnoea1
Febrile neutropenia1
Infusion related reaction1
Sepsis1
Septic shock1
Shock1
Stevens-Johnson syndrome1
SecondaryOverall Response Rate

The overall response rate (ORR) was defined as the percentage of participants with best overall response of Complete Response (CR) or Partial Response (PR), confirmed by repeat assessment no less than 4 weeks after the response criteria were first met, using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Participants who either had not achieved CR or PR or were without a post-baseline tumor assessment were to be considered non-responders. All measurable and non-measurable lesions were documented at screening and re-assessed at each subsequent tumor evaluation. Response was assessed by the investigator on the basis of physical examinations, computed tomography (CT) scans, and magnetic resonance imaging (MRI). The same radiographic procedure was used throughout the study, and assessments were preferably performed by the same evaluator. The 95% confidence intervals were calculated using Clopper-Pearson methodology.

Time frame:
From Baseline up to disease progression or death (assessed at every 9 weeks, up to approximately 3 years)
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsPertuzumab in Combination With Trastuzumab and Docetaxel
Responders (ORR)82.7 (69.67 to 91.77)
Non-Responders17.3 (8.23 to 30.33)
SecondaryNumber of Participants by Best Overall Response

The best overall response was defined as the best response, out of all the documented responses over the course of the entire study period, using RECIST v1.1. All measurable and non-measurable lesions were documented at screening and re-assessed at each subsequent tumor evaluation. Response was assessed by the investigator on the basis of physical examinations, computed tomography (CT) scans, and magnetic resonance imaging (MRI). The same radiographic procedure was used throughout the study, and assessments were preferably performed by the same evaluator.

Time frame:
From Baseline up to disease progression or death (assessed at every 9 weeks, up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants by Best Overall Response
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Complete Response (CR)0
Partial Response (PR)43
Progressive Disease (PD)1
Stable Disease (SD)6
Unable to Assess2
SecondaryNumber of Participants With Disease Progression or Death or Who Were Censored for Progression-Free Survival Analysis

Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Participants who had not progressed or died or were lost to follow up at the time of the analysis were censored on the last visit at which assessment for progression was done (2 years after the last participant was enrolled). PFS was analyzed by the Kaplan-Meier method.

Time frame:
From Baseline up to disease progression or death (assessed at every 9 weeks, up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Disease Progression or Death or Who Were Censored for Progression-Free Survival Analysis
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Disease Progression or Death32
Censored20
SecondaryMedian Duration of Progression-Free Survival

Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Participants who had not progressed or died, or were lost to follow up at the time of the analysis, were censored on the last visit at which assessment for progression was done (2 years after the last participant was enrolled). PFS was analyzed by the Kaplan-Meier method.

Time frame:
From Baseline up to disease progression or death (assessed at every 9 weeks, up to approximately 3 years)
Reported as:
Median · months
Median Duration of Progression-Free Survival
monthsPertuzumab in Combination With Trastuzumab and Docetaxel
Median Duration of Progression-Free Survival23.0 (13.0 to 29.0)
SecondaryProbability of Participants Remaining Event-Free in Progression-Free Survival From 2 to 32 Months

Progression-free survival (PFS) was defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Participants who had not progressed, died or were lost to follow up at the time of the analysis were censored on the last visit at which assessment for progression was done (2 years after the last participant was enrolled). PFS was analyzed by the Kaplan-Meier method.

Time frame:
Months 2, 3, 5, 6, 7, 8, 9, 11, 13, 15, 16, 17, 18, 19, 23, 24, 25, 27, 29, and 32
Reported as:
Number · Percent probability of PFS
Probability of Participants Remaining Event-Free in Progression-Free Survival From 2 to 32 Months
Percent probability of PFSPertuzumab in Combination With Trastuzumab and Docetaxel
At 2 Months98.08
At 3 Months96.15
At 5 Months90.27
At 6 Months88.30
At 7 Months82.42
At 8 Months78.49
At 9 Months74.57
At 11 Months68.52
At 13 Months64.49
At 15 Months60.33
At 16 Months58.10
At 17 Months55.86
At 18 Months53.63
At 19 Months51.30
At 23 Months48.96
At 24 Months46.63
At 25 Months41.72
At 27 Months36.16
At 29 Months32.87
At 32 Months29.59
SecondaryNumber of Participants Who Died or Were Censored for Overall Survival Analysis

Overall survival was defined as the time from enrollment to the the date of death from any cause. Participants who were alive at the time of the analysis, dropped out of the study, or lost to follow-up were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication, and participants with no post-baseline information were censored at baseline. Overall survival was analyzed by the Kaplan-Meier method.

Time frame:
From Baseline up to death from any cause (up to approximately 3 years)
Reported as:
Count of participants · Participants
Number of Participants Who Died or Were Censored for Overall Survival Analysis
ParticipantsPertuzumab in Combination With Trastuzumab and Docetaxel
Death15
Censored37
SecondaryMedian Duration of Overall Survival

Overall survival was defined as the time from enrollment to the the date of death from any cause. Participants who were alive at the time of the analysis, dropped out of the study, or lost to follow-up were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication, and participants with no post-baseline information were censored at baseline. Overall survival was analyzed by the Kaplan-Meier method.

Time frame:
From Baseline up to death from any cause (up to approximately 3 years)
Reported as:
Median · months
Median Duration of Overall Survival
monthsPertuzumab in Combination With Trastuzumab and Docetaxel
Median Duration of Overall SurvivalNA (26 to NA)
SecondaryProbability of Participants Remaining Alive in Overall Survival From 3 to 34 Months

Overall survival was defined as the time from enrollment to the the date of death from any cause. Participants who were alive at the time of the analysis, dropped out of the study, or lost to follow-up were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication, and participants with no post-baseline information were censored at baseline. Overall survival was analyzed by the Kaplan-Meier method.

Time frame:
Months 3, 9, 13, 14, 15, 18, 19, 20, 24, 25, 27, 32, 33, and 34
Reported as:
Number · Percent probability of OS
Probability of Participants Remaining Alive in Overall Survival From 3 to 34 Months
Percent probability of OSPertuzumab in Combination With Trastuzumab and Docetaxel
At 3 Months96.15
At 9 Months88.30
At 13 Months88.30
At 14 Months88.30
At 15 Months88.30
At 18 Months83.66
At 19 Months83.66
At 20 Months83.66
At 24 Months81.12
At 25 Months81.12
At 27 Months68.14
At 32 Months68.14
At 33 Months64.36
At 34 Months64.36

Adverse events

Collected over From Baseline until end of study (up to 3 years). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pertuzumab in Combination With Trastuzumab and Docetaxel15/52 (28.8%)31/52 (59.6%)47/52 (90.4%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPertuzumab in Combination With Trastuzumab and Docetaxel
Disease progressionGeneral disorders6/52
DiarrhoeaGastrointestinal disorders5/52
DeathGeneral disorders3/52
FatigueGeneral disorders3/52
Ejection fraction decreasedInvestigations3/52
DyspnoeaRespiratory, thoracic and mediastinal disorders3/52
Febrile neutropeniaBlood and lymphatic system disorders2/52
Left ventricular dysfunctionCardiac disorders2/52
Multiple organ dysfunction syndromeGeneral disorders2/52
Septic shockInfections and infestations2/52
Most frequent other events
Showing 10 of 129
Most frequent other events
EventPertuzumab in Combination With Trastuzumab and Docetaxel
DiarrhoeaGastrointestinal disorders17/52
StomatitisGastrointestinal disorders8/52
AnaemiaBlood and lymphatic system disorders8/52
PyrexiaGeneral disorders8/52
Pain in extremityMusculoskeletal and connective tissue disorders8/52
FatigueGeneral disorders8/52
Back painMusculoskeletal and connective tissue disorders7/52
CoughRespiratory, thoracic and mediastinal disorders7/52
VomitingGastrointestinal disorders6/52
HeadacheNervous system disorders6/52

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pertuzumab in Combination With Trastuzumab and Docetaxel
Mean50.2 ± 9.05
Sex: Female, Male
Sex: Female, Male(Participants)Pertuzumab in Combination With Trastuzumab and Docetaxel
Female52
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pertuzumab in Combination With Trastuzumab and Docetaxel
Race: Asian52
Ethnicity: Indian Subcontinent52
Diagnosis of Metastatic or Locally Recurrent Breast Cancer
Diagnosis of Metastatic or Locally Recurrent Breast Cancer(Participants)Pertuzumab in Combination With Trastuzumab and Docetaxel
Metastatic52
Locally Recurrent0
Histological Grade of Breast Cancer
Histological Grade of Breast Cancer(Participants)Pertuzumab in Combination With Trastuzumab and Docetaxel
Well Differentiated14
Moderately Differentiated16
Poorly Differentiated11
Anaplastic0
Unknown11
Breast Cancer Subtype by Histology
Breast Cancer Subtype by Histology(Participants)Pertuzumab in Combination With Trastuzumab and Docetaxel
Ductal47
Lobular0
Other5
Presence or Absence of Ductal Carcinoma In Situ (DCIS)
Presence or Absence of Ductal Carcinoma In Situ (DCIS)(Participants)Pertuzumab in Combination With Trastuzumab and Docetaxel
DCIS Present22
DCIS Absent29
DCIS Assessment Missing1
HER2-Positive Breast Cancer Confirmation Method
HER2-Positive Breast Cancer Confirmation Method(Participants)Pertuzumab in Combination With Trastuzumab and Docetaxel
Immunohistochemistry (IHC)31
In Situ Hybridization (ISH)1
Both IHC and ISH20

4 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • Rajiv Gandhi Cancer Institute & Research Center
    New Delhi, Delhi 110 085, India
  • Tata Memorial Hospital; Dept of Medical Oncology
    Mumbai, Maharashtra 400012, India
  • Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute
    Mumbai, Maharashtra 400053, India
  • Jehangir Clinical Development Centre Pvt. Ltd; Cancer Research Room
    Pune, Maharashtra 411001, India
  • Christian Medical College & Hospital; Medicine
    Vellore, Tamil NADU 632004, India
  • Indo-American Cancer Hospital & Research Center
    Hyderabad, Telangana 500034, India
  • TATA Medical Centre; Medical Oncology
    Kolkata, WEST Bengal 700156, India
  • M S Ramaiah Memorial Hospital
    Bangalore, 560054, India
  • MAX Balaji Hospital
    Delhi, 110092, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Sep 2018, 37 months.

Results were first posted in Oct 2019, 1 year 1 month after primary completion.

Of 130 phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2015
First posted
May 15, 2015
StartActual
Aug 17, 2015
Primary completionActual
Sep 26, 2018
CompletionActual
Sep 26, 2018
Results first posted
Oct 29, 2019
Last update
Oct 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02445586
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 15, 2015
Start date
Aug 17, 2015
Primary completion
Sep 26, 2018
Completion
Sep 26, 2018
Results posted
Oct 29, 2019
Last update
Oct 29, 2019

Study contacts

Anil Kukreja, MD
study director · Roche Products (India) Pvt. Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Pertuzumab

Start the discussion